Michiel R. de Boer

Michiel R. de Boer

Auto-generated profile, based on publicly available information

Michiel R. de Boer

Department of Primary and Long-term Care, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2007 in Journal of Clinical Epidemiology
Verified
Journal Article
Closed access
CTCaroline B. Terwee
Caroline B. Terwee
SBSandra D.M. Bot
Sandra D.M. Bot
MBMichael R. de Boer
Michael R. de Boer
DWDaniëlle A.W.M. van der Windt
Daniëlle A.W.M. van der Windt
DKDirk L. Knol
Dirk L. Knol
HVHenrica C.W. de Vet
Henrica C.W. de Vet

1 September 2013 in Journal of Clinical Epidemiology
Verified
Journal Article
Closed access
JTJos Twisk
Jos Twisk
MBMichiel de Boer
Michiel de Boer
WVWieke de Vente
Wieke de Vente
MHMartijn Heymans
Martijn Heymans

24 January 2015 in International Journal of Behavioral Nutrition and Physical Activity
Verified
Journal Article
Open access
PDF file
MBMichiel R de Boer
Michiel R de Boer
WWWilma E Waterlander
Wilma E Waterlander
LKLothar Dj Kuijper
Lothar Dj Kuijper
ISIngrid Steenhuis
Ingrid Steenhuis
JTJos Twisk
Jos Twisk
According to the CONSORT statement, significance testing of baseline differences in randomized controlled trials should not be performed. In fact, this practice has been discouraged by numerous authors throughout the last forty years. During that time span, reporting of baseline differences has substantially decreased in the leading general medical journals. Our own experience in the field of nutrition behavior research however, is that co-authors, reviewers and even editors are still very persistent in their demand for these tests. The aim of this paper is therefore to negate this demand by providing clear evidence as to why testing for baseline differences between intervention groups statistically is superfluous and why such results should not be published. Testing for baseline differences is often propagated because of the belief that it shows whether randomization was successful and it identifies real or important differences between treatment arms that should be accounted for in the statistical analyses. Especially the latter argument is flawed, because it ignores the fact that the prognostic strength of a variable is also important when the interest is in adjustment for confounding. In addition, including prognostic variables as covariates can increase the precision of the effect estimate. This means that choosing covariates based on significance tests for baseline differences might lead to omissions of important covariates and, less importantly, to inclusion of irrelevant covariates in the analysis. We used data from four supermarket trials on the effects of pricing strategies on fruit and vegetables purchases, to show that results from fully adjusted analyses sometimes do appreciably differ from results from analyses adjusted for significant baseline differences only. We propose to adjust for known or anticipated important prognostic variables. These could or should be pre-specified in trial protocols. Subsequently, authors should report results from the fully adjusted as well as crude analyses, especially for dichotomous and time to event data. Based on our arguments, which were illustrated by our findings, we propose that journals in and outside the field of nutrition behavior actively adopt the CONSORT 2010 statement on this topic by not publishing significance tests for baseline differences anymore.

13 March 2019 in BMJ
Verified
Journal Article
Open access
PDF file
SRSidney M Rubinstein
Sidney M Rubinstein
AZAnnemarie de Zoete
Annemarie de Zoete
MMMarienke van Middelkoop
Marienke van Middelkoop
WAWillem J J Assendelft
Willem J J Assendelft
MBMichiel R de Boer
Michiel R de Boer
MTMaurits W van Tulder
Maurits W van Tulder
Objective To assess the benefits and harms of spinal manipulative therapy (SMT) for the treatment of chronic low back pain. Design Systematic review and meta-analysis of randomised controlled trials. Data sources Medline, PubMed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), CINAHL, Physiotherapy Evidence Database (PEDro), Index to Chiropractic Literature, and trial registries up to 4 May 2018, including reference lists of eligible trials and related reviews. Eligibility criteria for selecting studies Randomised controlled trials examining the effect of spinal manipulation or mobilisation in adults (≥18 years) with chronic low back pain with or without referred pain. Studies that exclusively examined sciatica were excluded, as was grey literature. No restrictions were applied to language or setting. Review methods Two reviewers independently selected studies, extracted data, and assessed risk of bias and quality of the evidence. The effect of SMT was compared with recommended therapies, non-recommended therapies, sham (placebo) SMT, and SMT as an adjuvant therapy. Main outcomes were pain and back specific functional status, examined as mean differences and standardised mean differences (SMD), respectively. Outcomes were examined at 1, 6, and 12 months. Quality of evidence was assessed using GRADE. A random effects model was used and statistical heterogeneity explored. Results 47 randomised controlled trials including a total of 9211 participants were identified, who were on average middle aged (35-60 years). Most trials compared SMT with recommended therapies. Moderate quality evidence suggested that SMT has similar effects to other recommended therapies for short term pain relief (mean difference −3.17, 95% confidence interval −7.85 to 1.51) and a small, clinically better improvement in function (SMD −0.25, 95% confidence interval −0.41 to −0.09). High quality evidence suggested that compared with non-recommended therapies SMT results in small, not clinically better effects for short term pain relief (mean difference −7.48, −11.50 to −3.47) and small to moderate clinically better improvement in function (SMD −0.41, −0.67 to −0.15). In general, these results were similar for the intermediate and long term outcomes as were the effects of SMT as an adjuvant therapy. Evidence for sham SMT was low to very low quality; therefore these effects should be considered uncertain. Statistical heterogeneity could not be explained. About half of the studies examined adverse and serious adverse events, but in most of these it was unclear how and whether these events were registered systematically. Most of the observed adverse events were musculoskeletal related, transient in nature, and of mild to moderate severity. One study with a low risk of selection bias and powered to examine risk (n=183) found no increased risk of an adverse event (relative risk 1.24, 95% confidence interval 0.85 to 1.81) or duration of the event (1.13, 0.59 to 2.18) compared with sham SMT. In one study, the Data Safety Monitoring Board judged one serious adverse event to be possibly related to SMT. Conclusion SMT produces similar effects to recommended therapies for chronic low back pain, whereas SMT seems to be better than non-recommended interventions for improvement in function in the short term. Clinicians should inform their patients of the potential risks of adverse events associated with SMT.

1 February 2012 in Environmental Health Perspectives
Verified
Journal Article
Open access
EGEva Govarts
Eva Govarts
MNMark Nieuwenhuijsen
Mark Nieuwenhuijsen
Greet  SchoetersGreet Schoeters
Greet Schoeters
FBFerran Ballester
Ferran Ballester
KBKarolien Bloemen
Karolien Bloemen
OEObelix/ Enrieco
Obelix/ Enrieco
A peer-reviewed open access journal published by the National Institute of Environmental Health Sciences

1 March 2014 in Journal of Clinical Epidemiology
Verified
Journal Article
Closed access
IEIris Eekhout
Iris Eekhout
HVHenrica C.W. de Vet
Henrica C.W. de Vet
JTJos W.R. Twisk
Jos W.R. Twisk
JBJaap P.L. Brand
Jaap P.L. Brand
MBMichiel R. de Boer
Michiel R. de Boer
MHMartijn W. Heymans
Martijn W. Heymans